From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants.

Authors:
Papanikolaou V; Chrysovergis A; Ragos V; Tsiambas E; Katsinis S and 8 more

Journal:
Gene

Publication Year: 2022

DOI:
10.1016/j.gene.2021.146134

PMCID:
PMC8725615

PMID:
34990799

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Gene

Abbreviation: Gene

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Emerging role of microRNAs and long non-coding RNAs in COVID-19 with implications to therapeutics.
Arman K; Dalloul Z; Bozgeyik E. (2023) - Transparency Score: 3/6
Human T-lymphotropic virus type 1 and novel coronavirus disease 2019; More complex than just a simp…
Sajjadi S; Hejazi S; Ravanshad S and 1 more (2022) - Transparency Score: 2/6
In silico analysis of genomic landscape of SARS-CoV-2 and its variant of concerns (Delta and Omicro…
Saini S; Khurana S; Saini D and 7 more (2022) - Transparency Score: 4/6
Loss of furin site enhances SARS-CoV-2 spike protein pseudovirus infection.
Wang Z; Zhong K; Wang G and 10 more (2022) - Transparency Score: 4/6
Palindromic target site identification in SARS-CoV-2, MERS-CoV and SARS-CoV-1 by adopting CRISPR-Ca…
Ghosh N; Saha I; Sharma N. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025